Neuraxis (NRXS) Cash from Investing Activities (2022 - 2025)
Neuraxis (NRXS) posted Cash from Investing Activities of -$105862.0 for Q4 2025, down 1352.55% sequentially from -$7288.0 in Q2 2025.
Neuraxis (NRXS) Cash from Investing Activities (2022 - 2025) Analysis & Trends
Neuraxis has reported Cash from Investing Activities for 4 years, with the latest figure at -$105862.0 in Q4 2025.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$105862.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$131150.0 (down 372.17% YoY) and the FY2025 annual result came in at -$131150.0, down 372.17% from the prior year.
- Cash from Investing Activities fell to -$105862.0 in Q4 2025 per NRXS's latest filing, from -$7288.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $38425.0 in Q3 2022 and troughed at -$105862.0 in Q4 2025.
- A 4-year average of -$20174.8 and a median of -$11704.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 211.06% in 2023, then jumped 89.76% in 2024.
- Over 4 years, Cash from Investing Activities stood at -$49815.0 in 2022, then surged by 67.8% to -$16040.0 in 2023, then soared by 72.77% to -$4368.0 in 2024, then tumbled by 2323.58% to -$105862.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$105862.0, -$7288.0, and -$18000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -105,862.00 |
| Dec 31, 2025 | -105,862.00 |
| Jun 30, 2025 | -7,288.00 |
| Jun 30, 2025 | -7,288.00 |
| Mar 31, 2025 | -18,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Sep 30, 2024 | -4,368.00 |
| Sep 30, 2024 | -4,368.00 |
| Jun 30, 2024 | -8,686.00 |
| Jun 30, 2024 | -8,686.00 |
| Mar 31, 2024 | -14,722.00 |
| Mar 31, 2024 | -14,722.00 |
| Dec 31, 2023 | -16,040.00 |
| Dec 31, 2023 | -16,040.00 |
| Sep 30, 2023 | -42,674.00 |
| Sep 30, 2023 | -42,674.00 |
| Jun 30, 2023 | -5,459.00 |
| Jun 30, 2023 | -5,459.00 |
| Mar 31, 2023 | -7,608.00 |
| Mar 31, 2023 | -7,608.00 |